Imatinib Completed Phase 2 Trials for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00154349Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia